Status:

UNKNOWN

Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19

Lead Sponsor:

Cadila Pharnmaceuticals

Collaborating Sponsors:

Council of Scientific and Industrial Research, India

Conditions:

COVID-19

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This clinical trial is a randomized, blinded, two arms, placebo controlled, clinical trial to evaluate the safety and efficacy of Mycobacterium w in combination with standard care as per hospital prac...

Detailed Description

Approximately eligible 4000 subjects who are at risk of getting infected with COVID-19 (i.e. person living in same household as COVID-19 patients / healthcare workers providing direct care to COVID-19...

Eligibility Criteria

Inclusion

  • Healthy subjects of either gender, age ≥ 18 years, with recent history of close contact with COVID-19 patients.
  • Subjects with SARS Cov 2 negative test (ICMR approved test kit) at screening visit.
  • Female subject who are currently using reliable methods of contraception (barrier methods and intrauterine contraceptive device), with a negative urine pregnancy test during screening and agree to informed compliance of contraceptive method until at least months post-dosing.
  • The subject must be able and willing to comply with the study protocol, available and willing to complete all the study assessments and must have signed an Informed Consent Form.

Exclusion

  • Any febrile illness with oral temperature \> 100°F within 3 days prior to randomization.
  • Subject with past history of COVID-19 infection.
  • Pregnant and / or lactating female subjects.
  • Presence of any illness requiring hospital referral.
  • Any confirmed or suspected immune-deficient condition based on medical history and physical examination and a family history of congenital or hereditary immunodeficiency or Individuals on immunosuppressant's as Azathioprine, Cyclosporine, Mycophenolate etc.
  • History of allergic reactions or anaphylaxis to Mw or its component.

Key Trial Info

Start Date :

June 30 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 30 2021

Estimated Enrollment :

4000 Patients enrolled

Trial Details

Trial ID

NCT04353518

Start Date

June 30 2020

End Date

May 30 2021

Last Update

December 22 2020

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

All India Institute of Medical Sciences, Bhopal

Bhopal, Madhya Pradesh, India, 462024

2

Post Graduate Institute of Medical Education and Research

Chandigarh, India, 160012.

3

All lndia Institute of Medical Science, Delhi

Delhi, India, 110029